NCT04983823Recruiting
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
Source: ClinicalTrials.gov · Last updated 3 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 820 (estimated)
- First submitted
- 29 Jul 2021
- Start date
- 18 Nov 2021
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Baker Heart and Diabetes Institute
- Diseases
- Heart failure
- NCT number
- NCT04983823
What you commit to
- Study type: Interventional
- Planned participants: 820
- From 18 Nov 2021 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2)
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
Other illness
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
- Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.
- Mobility impairment that would impact participants' ability to perform exercise
Other
- Valvular stenosis or regurgitation of \>moderate severity
- Inability to acquire interpretable images (identified from baseline echo)
- Unable to provide written informed consent to participate in this study
Who the study is looking for
- History of COVID-19 infection
- Live within a geographically accessible area for follow-up
Age in the registry: 50 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baker Heart and Diabetes Institute Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.